Tiprelestat: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -189% 1 17 Improvement, Studies, Patients Relative Risk Mortality -189% 1 17 ICU admission 22% 1 17 RCTs -189% 1 17 Late -189% 1 17 Tiprelestat for COVID-19 c19early.org May 2026 Favorstiprelestat Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) -189% 2.89 [0.13-62.3] death 1/9 0/8 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk All studies -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk 1 tiprelestat COVID-19 study c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors tiprelestat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) -189% 2.89 [0.13-62.3] 1/9 0/8 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk All studies -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk 1 tiprelestat COVID-19 mortality result c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Favors tiprelestat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) 22% 0.78 [0.07-8.65] 9 (n) 8 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Late treatment 22% 0.78 [0.07-8.65] 9 (n) 8 (n) 22% lower risk All studies 22% 0.78 [0.07-8.65] 9 (n) 8 (n) 22% lower risk 1 tiprelestat COVID-19 ICU result c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.85 Favors tiprelestat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) -189% 2.89 [0.13-62.3] death 1/9 0/8 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk All studies -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk 1 tiprelestat COVID-19 Randomized Controlled Trial c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors tiprelestat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) -189% 2.89 [0.13-62.3] 1/9 0/8 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk All studies -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk 1 tiprelestat COVID-19 RCT mortality result c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Favors tiprelestat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) -189% 2.89 [0.13-62.3] death 1/9 0/8 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk All studies -189% 2.89 [0.13-62.3] 1/9 0/8 189% higher risk 1 tiprelestat COVID-19 peer reviewed studies c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors tiprelestat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bergs (DB RCT) -189% 2.89 [0.13-62.3] death 1/9 0/8 Improvement, RR [CI] Treatment Control Bergs (DB RCT) 11% 0.89 [0.07-12.0] progression 1/9 1/8 Bergs (DB RCT) 22% 0.78 [0.07-8.65] ICU 9 (n) 8 (n) Bergs (DB RCT) 40% 0.60 [0.13-2.73] oxygen time 9 (n) 8 (n) Tiprelestat COVID-19 outcomes c19early.org May 2026 Favors tiprelestat Favors control